Brian G Stultz1, Kathleen McGinnis1, Elaine E Thompson1, Jessica L Lo Surdo1, Steven R Bauer1, Deborah A Hursh2. 1. Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. 2. Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: deborah.hursh@fda.hhs.gov.
Abstract
BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) are being investigated for use in cell therapy. The extensive in vitro expansion necessary to obtain sufficient cells for clinical use increases the risk that genetically abnormal cells will arise and be propagated during cell culture. Genetic abnormalities may lead to transformation and poor performance in clinical use, and are a critical safety concern for cell therapies using MSCs. METHODS: We used spectral karyotyping (SKY) to investigate the genetic stability of human MSCs from ten donors during passaging. RESULTS: Our data indicate that chromosomal abnormalities exist in MSCs at early passages and can be clonally propagated. The karyotypic abnormalities observed during our study diminished during passage. CONCLUSIONS: Karyotyping of MSCs reveals characteristics which may be valuable in deciding the suitability of cells for further use. Karyotypic analysis is useful for monitoring the genetic stability of MSCs during expansion. Published by Elsevier Inc.
BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) are being investigated for use in cell therapy. The extensive in vitro expansion necessary to obtain sufficient cells for clinical use increases the risk that genetically abnormal cells will arise and be propagated during cell culture. Genetic abnormalities may lead to transformation and poor performance in clinical use, and are a critical safety concern for cell therapies using MSCs. METHODS: We used spectral karyotyping (SKY) to investigate the genetic stability of human MSCs from ten donors during passaging. RESULTS: Our data indicate that chromosomal abnormalities exist in MSCs at early passages and can be clonally propagated. The karyotypic abnormalities observed during our study diminished during passage. CONCLUSIONS: Karyotyping of MSCs reveals characteristics which may be valuable in deciding the suitability of cells for further use. Karyotypic analysis is useful for monitoring the genetic stability of MSCs during expansion. Published by Elsevier Inc.
Authors: Luc Sensebé; Karin Tarte; Jacques Galipeau; Mauro Krampera; Ivan Martin; Donald G Phinney; Yufang Shi Journal: Cell Stem Cell Date: 2012-01-06 Impact factor: 24.633
Authors: Samuel T Mindaye; Moonjin Ra; Jessica L Lo Surdo; Steven R Bauer; Michail A Alterman Journal: Stem Cell Res Date: 2013-06-02 Impact factor: 2.020
Authors: Sumati Sundaram; Jennifer One; Joshua Siewert; Stephan Teodosescu; Liping Zhao; Sashka Dimitrievska; Hong Qian; Angela H Huang; Laura Niklason Journal: Stem Cells Transl Med Date: 2014-11-05 Impact factor: 6.940
Authors: Qiuwei Pan; Suomi M G Fouraschen; Petra E de Ruiter; Winand N M Dinjens; Jaap Kwekkeboom; Hugo W Tilanus; Luc J W van der Laan Journal: Exp Biol Med (Maywood) Date: 2013-11-13
Authors: Matthew W Klinker; Ross A Marklein; Jessica L Lo Surdo; Cheng-Hong Wei; Steven R Bauer Journal: Proc Natl Acad Sci U S A Date: 2017-03-10 Impact factor: 11.205
Authors: Andrea L DiCarlo; Radia Tamarat; Carmen I Rios; Marc Benderitter; Christine W Czarniecki; Theresa C Allio; Francesca Macchiarini; Bert W Maidment; Jean-Rene Jourdain Journal: Radiat Res Date: 2017-06-12 Impact factor: 2.841
Authors: Yazmin I Rovira Gonzalez; Patrick J Lynch; Elaine E Thompson; Brian G Stultz; Deborah A Hursh Journal: Cytotherapy Date: 2016-07-12 Impact factor: 5.414
Authors: Arantza Campo; José María González-Ruiz; Enrique Andreu; Ana B Alcaide; María M Ocón; Juan De-Torres; Jesús Pueyo; Rosa Cordovilla; Eva Villaron; Fermín Sanchez-Guijo; Miguel Barrueco; Jorge Nuñez-Córdoba; Felipe Prósper; Javier J Zulueta Journal: ERJ Open Res Date: 2021-06-28